​

Cullinan Therapeutics Stock (NASDAQ:CGEM)

ForecastOwnershipFinancialsChart
Cullinan Therapeutics by TradingView

Previous Close

$6.47

52W Range

$6.44 - $18.62

50D Avg

$7.62

200D Avg

$8.98

Market Cap

$391.07M

Avg Vol (3M)

$404.16K

Beta

-0.07

Div Yield

-

CGEM Company Profile

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Show More

Industry

Medical - Pharmaceuticals

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

111

IPO Date

Jan 08, 2021

Website

CGEM Performance

CGEM Financial Summary

Dec 23Dec 22Dec 21
Revenue--$18.94M
Operating Income$-191.09M$144.65M$-67.95M
Net Income$-153.16M$111.21M$-65.04M
EBITDA$-190.34M$151.41M$-67.90M
Basic EPS$-3.69$2.46$-1.47
Diluted EPS$-3.69$2.38$-1.47

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
IMCRImmunocore Holdings plc
DSGNDesign Therapeutics, Inc.
GLUEMonte Rosa Therapeutics, Inc.
ERASErasca, Inc.
BCABBioAtla, Inc.
VORVor Biopharma Inc.